170 related articles for article (PubMed ID: 12768357)
1. Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome.
Saletu M; Anderer P; Högl B; Saletu-Zyhlarz G; Kunz A; Poewe W; Saletu B
J Neural Transm (Vienna); 2003 Jun; 110(6):611-26. PubMed ID: 12768357
[TBL] [Abstract][Full Text] [Related]
2. Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome.
Saletu M; Anderer P; Saletu-Zyhlarz G; Hauer C; Saletu B
Eur Arch Psychiatry Clin Neurosci; 2002 Aug; 252(4):185-94. PubMed ID: 12242580
[TBL] [Abstract][Full Text] [Related]
3. One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome?
Trenkwalder C; Collado Seidel V; Kazenwadel J; Wetter TC; Oertel W; Selzer R; Kohnen R
Mov Disord; 2003 Oct; 18(10):1184-9. PubMed ID: 14534925
[TBL] [Abstract][Full Text] [Related]
4. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms.
Collado-Seidel V; Kazenwadel J; Wetter TC; Kohnen R; Winkelmann J; Selzer R; Oertel WH; Trenkwalder C
Neurology; 1999 Jan; 52(2):285-90. PubMed ID: 9932945
[TBL] [Abstract][Full Text] [Related]
5. On the pharmacotherapy of sleep bruxism: placebo-controlled polysomnographic and psychometric studies with clonazepam.
Saletu A; Parapatics S; Saletu B; Anderer P; Prause W; Putz H; Adelbauer J; Saletu-Zyhlarz GM
Neuropsychobiology; 2005; 51(4):214-25. PubMed ID: 15915004
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of idiopathic and uremic restless legs syndrome with L-dopa--a double-blind cross-over study].
Wetter TC; Trenkwalder C; Stiasny K; Pollmächer T; Kazenwadel J; Kohnen R; Künzel M; Oertel WH
Wien Med Wochenschr; 1995; 145(17-18):525-7. PubMed ID: 8588396
[TBL] [Abstract][Full Text] [Related]
7. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial.
Trenkwalder C; Stiasny K; Pollmächer T; Wetter T; Schwarz J; Kohnen R; Kazenwadel J; Krüger HP; Ramm S; Künzel M
Sleep; 1995 Oct; 18(8):681-8. PubMed ID: 8560135
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR).
Oertel WH; Benes H; Bodenschatz R; Peglau I; Warmuth R; Happe S; Geisler P; Cassel W; Leroux M; Kohnen R; Stiasny-Kolster K
Neurology; 2006 Sep; 67(6):1040-6. PubMed ID: 16931508
[TBL] [Abstract][Full Text] [Related]
9. Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial.
Benes H; Kurella B; Kummer J; Kazenwadel J; Selzer R; Kohnen R
Sleep; 1999 Dec; 22(8):1073-81. PubMed ID: 10617168
[TBL] [Abstract][Full Text] [Related]
10. Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid.
Eisensehr I; Ehrenberg BL; Rogge Solti S; Noachtar S
J Neurol; 2004 May; 251(5):579-83. PubMed ID: 15164191
[TBL] [Abstract][Full Text] [Related]
11. Sleep laboratory study on single and repeated dose effects of paroxetine, alprazolam and their combination in healthy young volunteers.
Barbanoj MJ; Clos S; Romero S; Morte A; Giménez S; Lorenzo JL; Luque A; Dal-Ré R
Neuropsychobiology; 2005; 51(3):134-47. PubMed ID: 15838185
[TBL] [Abstract][Full Text] [Related]
12. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality.
Saletu B; Gruber G; Saletu M; Brandstätter N; Hauer C; Prause W; Ritter K; Saletu-Zyhlarz G
Neuropsychobiology; 2000; 41(4):181-9. PubMed ID: 10828727
[TBL] [Abstract][Full Text] [Related]
13. Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial.
Bassetti CL; Bornatico F; Fuhr P; Schwander J; Kallweit U; Mathis J;
Swiss Med Wkly; 2011; 141():w13274. PubMed ID: 22101745
[TBL] [Abstract][Full Text] [Related]
14. Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome.
Polo O; Ylä-Sahra R; Hirvonen K; Karvinen J; Vahteristo M; Ellmén J
Clin Neuropharmacol; 2007; 30(6):335-44. PubMed ID: 18090458
[TBL] [Abstract][Full Text] [Related]
15. A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: polysomnographic evaluation of periodic leg movements and sleep disturbance.
Jama L; Hirvonen K; Partinen M; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
Sleep Med; 2009 Jun; 10(6):630-6. PubMed ID: 19171500
[TBL] [Abstract][Full Text] [Related]
16. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study.
Garcia-Borreguero D; Larrosa O; Williams AM; Albares J; Pascual M; Palacios JC; Fernandez C
Neurology; 2010 Jun; 74(23):1897-904. PubMed ID: 20427750
[TBL] [Abstract][Full Text] [Related]
17. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies.
Fulda S; Wetter TC
Brain; 2008 Apr; 131(Pt 4):902-17. PubMed ID: 17932100
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: A polysomnographic randomized, double-blind, placebo-controlled study.
Inoue Y; Hirata K; Kuroda K; Fujita M; Shimizu T; Emura N; Uchimura N; Kagimura T; Sha K; Nozawa T
Sleep Med; 2010 Jan; 11(1):11-6. PubMed ID: 19962941
[TBL] [Abstract][Full Text] [Related]
19. Restless legs syndrome: clinical experience with long-term treatment.
Clavadetscher SC; Gugger M; Bassetti CL
Sleep Med; 2004 Sep; 5(5):495-500. PubMed ID: 15341896
[TBL] [Abstract][Full Text] [Related]
20. L-DOPA/carbidopa for nocturnal movement disorders in uremia.
Walker SL; Fine A; Kryger MH
Sleep; 1996 Apr; 19(3):214-8. PubMed ID: 8723378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
